Clinical Trial Update: Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports results from a Phase 1/2 study of trastuzumab combined with RAD001 (everolimus) in HER-2 overexpressing breast cancer. The tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Afinitor (everolimus)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Breast Cancer, Neoplasm Metastasis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-06-12